News
CELC
90.79
-2.14%
-1.99
Weekly Report: what happened at CELC last week (0803-0807)?
Weekly Report · 1d ago
CELC SHAREHOLDER ALERT: Celcuity Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
Barchart · 08/03 19:19
Most and least shorted mid- to mega-cap healthcare stocks at the end of July
Seeking Alpha · 08/03 13:35
Weekly Report: what happened at CELC last week (0727-0731)?
Weekly Report · 08/03 09:05
CELC Investors Have Opportunity to Join Celcuity Inc. Fraud Investigation with SBS Law
PR Newswire · 08/03 05:08
Celcuity announces NCCN recommendation for Revtorpyk combination
TipRanks · 07/30 13:40
Celcuity's REVTORPYK Receives Recommendation From National Comprehensive Cancer Network Clinical Practice Guidelines In Oncology As Preferred Category 1 Second-Line Therapy
Benzinga · 07/30 12:34
NASDAQ: CELC Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm
Barchart · 07/28 18:50
Weekly Report: what happened at CELC last week (0720-0724)?
Weekly Report · 07/27 09:05
Short Report: Bears book profits in Celcuity
TipRanks · 07/26 14:50
These healthcare stocks are trading near oversold levels as earnings season picks up
Seeking Alpha · 07/21 12:54
Weekly Report: what happened at CELC last week (0713-0717)?
Weekly Report · 07/20 09:05
Weekly Buzz: NVS, MRK Win FDA Nod; LLY Snaps Up ATAI; MANE Shines On Hair Loss Data
NASDAQ · 07/18 05:19
Celcuity (CELC) Receives a Buy from Leerink Partners
TipRanks · 07/17 13:05
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC
Barchart · 07/16 18:52
Celcuity: 'Buy' REVTORPYK FDA Approval First And sNDA Label Expansion Q3 2026
Seeking Alpha · 07/15 17:45
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 07/15 17:05
Celcuity Shares Down, FDA Approval Outweighed by Timeline Questions for Breast-Cancer Treatment
Dow Jones · 07/15 16:06
Analysts’ Top Healthcare Picks: Denali Therapeutics (DNLI), Celcuity (CELC)
TipRanks · 07/15 14:40
More
Webull provides a variety of real-time CELC stock news. You can receive the latest news about Celcuity Inc through multiple platforms. This information may help you make smarter investment decisions.
About CELC
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a kinase inhibitor of phosphatidylinositol 3-kinase (PI3K), serine/threonine-protein kinase protein kinase B (AKT), mechanistic target of rapamycin (mTOR) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2. A Phase III clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) (HR+/HER2-) advanced breast cancer (ABC) has completed enrollment and reported detailed results for cohort 1, patients with PIK3CA wild-type (WT) tumors, and has completed enrollment of cohort 2, patients with PIK3CA mutant-type (MT) tumors.